CEFTIN ORAL SUSPENSION CEFUROXIME 250MG/5ML 50ML

Product Description

ZINNAT® is an oral prodrug of cefuroxime, the bactericidal cephalosporin antibiotic, resistant to most beta-lactamases and active against a wide variety of gram-positive and gram-negative microorganisms. It is indicated for the treatment of infections caused by sensitive bacteria. Susceptibility to ZINNAT® will vary with geography and time, and local susceptibility information should be consulted, where available (see Pharmacokinetics and Pharmacodynamics). Indications include: • Infections of the upper respiratory tract, for example, ear, nose and throat infections, such as otitis media, sinusitis, tonsillitis and pharyngitis. • Lower respiratory tract infections, eg pneumonia, acute bronchitis, and acute exacerbations of chronic bronchitis. • Genitourinary tract infections, for example pyelonephritis, cystitis and urethritis. • Infections of the skin and soft tissues, for example :, furunculosis, pyoderma and impetigo. • Gonorrhea, uncomplicated acute gonococcal urethritis, and cervicitis. • Treatment of early-stage Lyme disease and subsequent prevention of late-stage Lyme disease. Cefuroxime is also available as the sodium salt (ZINNAT® Solution for injection), for parenteral administration. This allows the use of sequential therapy with the same antibiotic in situations where a change from parenteral to oral therapy is clinically indicated. In suitable situations, ZINNAT® is effective when used after initial therapy with ZINNAT® (cefuroxime sodium) solution for injection, in the treatment of pneumonia and acute exacerbations of chronic bronchitis.